Market news

A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

The small-cap firm is likely to see defense by professional managers.

Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission to include subjects that have received multiple AXPAXLI injections in support of the Company’s application for repeat dosing Commercial readiness accelerates ahead of potential 2027 launch as AXPAXLI is well positioned to pote

On August 3, Ocular Therapeutix (NASDAQ:OCUL) reported second-quarter 2026 financial results that read as much like a regulatory update as an earnings report. Management confirmed that AXPAXLI, its lead retinal disease candidate, remains on track for a new drug application submission for wet age-related macular degeneration in the fourth quarter of 2026, a plan the […]

BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026. Upcoming Investor Conferences: Wells Fargo 21st Annual Healthcare Conference:Date: Thursday, September 10, 2026Ocular Therapeutix to host investor one-on-one meetingsLocation: Boston, MA Baird 2

Ocular Therapeutix recently reported Q2 results that topped revenue and EPS expectations and shared that its pivotal phase 3 AXPAXLI trials remain on track for an FDA-aligned NDA submission targeted for Q4 2026. This combination of operational outperformance and regulatory clarity around AXPAXLI’s development path highlights how closely the company’s near-term outlook is tied to this single retinal asset. Next, we’ll examine how the strong quarterly performance and FDA-aligned AXPAXLI...

Ocular Therapeutix (OCUL) is back in focus after its Q2 report, where revenues and earnings per share surpassed analyst expectations, and management outlined progress on AXPAXLI phase 3 trials with an FDA aligned path toward an NDA in Q4 2026. See our latest analysis for Ocular Therapeutix. Ocular Therapeutix shares have been volatile, with the 30 day share price return of 29.06% and 90 day share price return of 34.63% coming after Q2 results and recent investor events, while the 1 year total...

Ocular Therapeutix now carries an updated fair value estimate of about US$27.09 per share, up from US$26.00, reflecting refreshed price target work in recent modeling. Recent Street commentary links these higher targets in the mid to high US$20s to views on Axpaxli’s market opportunity, competitive trial readouts, and the latest FDA interactions. As you read on, you will see how to track these shifting assumptions and what to watch as the Ocular Therapeutix story continues to evolve. Analyst...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Ocular Therapeutix (NASDAQ:OCUL) and its peers.

EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD.

BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted...

BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listin

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The small-cap healthcare firm offered some encouraging earnings results.

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of +12.50% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at $13.48 million. Its GAAP loss of $0.35 per share was 11.2% above analysts’ consensus estimates.

Ocular Therapeutix: Q2 Earnings Snapshot

Ocular’s AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence as Sufficient to Support Submission of AXPAXLI NDA in wet AMD AXPAXLI NDA submission to be based on SOL-1 Week 52 efficacy and safety data, interim SOL-R safety data, and confirmatory evidence Pre-NDA meeting scheduled with FDA in Q3 2026 with the NDA submission to follow the Section 505(b)(2) pa

Let’s dig into the relative performance of Ocular Therapeutix (NASDAQ:OCUL) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings season.

Ocular Therapeutix (OCUL) has drawn investor attention after recent trading saw the stock close at $8.62, with returns under pressure over the past month and past 3 months despite positive annual revenue growth. See our latest analysis for Ocular Therapeutix. Over a longer horizon, Ocular Therapeutix’s share price has come under pressure, with the year to date share price return down 27.07%, while the 3 year total shareholder return is up 100%. This points to strong historical swings in...

Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman, President and CEO Dr. Pravin Dugel described as alignment with the U.S. Food and Drug Administration on

BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eleven newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule